Current studies have shown that the main factors influencing immunotherapy are: the tumor immune microenvironment, the tumor immunogenicity, the dysfunction of MHCs, irreversible T cell failure, and mutations in tumor genes including the interferon-gamma (IFN-γ) signaling pathway [5–7]. This evidence concerns the gene IFNG and neoplasm.